Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + Iberdomide + Dexamethasone in Elderly Multiple Myeloma at First Relapse
2021-001587-13Phase 2Active
- Sponsor
- CHU de Nantes
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib, iberdomide and dexamethasone in multiple myeloma (MM), sponsored by CHU de Nantes. Primary endpoint: VGPR or better rate. Started Aug 2021; status: active.
02
Drugs
ixazomibiberdomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-001587-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001587-13.